| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10916266 | Nuclear Medicine and Biology | 2005 | 7 Pages |
Abstract
Antibody pretargeting system with Mab-streptavidin, clearing agent and DOTA-biotin provides the potential of 212Bi for solid tumor radiotherapy despite the release of 212Bi after 212Pb decay. Dosimetry calculations resulted in tumor dose at 93 rad/μCi and ratios of tumor to marrow and kidney at 386:1 and 12:1, respectively.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Fu-Min Su, Paul Beaumier, Don Axworthy, Robert Atcher, Alan Fritzberg,